Gencurix Inc (229000) - Total Liabilities
Based on the latest financial reports, Gencurix Inc (229000) has total liabilities worth ₩15.69 Billion KRW (≈ $10.63 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Gencurix Inc - Total Liabilities Trend (2016–2024)
This chart illustrates how Gencurix Inc's total liabilities have evolved over time, based on quarterly financial data. See how liquid is Gencurix Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
Gencurix Inc Competitors by Total Liabilities
The table below lists competitors of Gencurix Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
KD Chem Co. Ltd
KQ:221980
|
Korea | ₩36.08 Billion |
|
CHAR Technologies Ltd
V:YES
|
Canada | CA$3.99 Million |
|
BIOCERES CROP SOL.
F:0G4
|
Germany | €453.75 Million |
|
Radiant Innovation
TWO:3373
|
Taiwan | NT$67.50 Million |
|
Beam Global
NASDAQ:BEEM
|
USA | $18.08 Million |
|
Mogo Inc
TO:MOGO
|
Canada | CA$101.48 Million |
|
Globalsat Worldcom
TWO:3499
|
Taiwan | NT$279.06 Million |
|
Cytosorbents Crp
NASDAQ:CTSO
|
USA | $38.37 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Gencurix Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Gencurix Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.71 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.63 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gencurix Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gencurix Inc (2016–2024)
The table below shows the annual total liabilities of Gencurix Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩15.15 Billion ≈ $10.27 Million |
-29.54% |
| 2023-12-31 | ₩21.50 Billion ≈ $14.57 Million |
-30.12% |
| 2022-12-31 | ₩30.76 Billion ≈ $20.85 Million |
+26.62% |
| 2021-12-31 | ₩24.30 Billion ≈ $16.47 Million |
+129.19% |
| 2020-12-31 | ₩10.60 Billion ≈ $7.18 Million |
+374.88% |
| 2019-12-31 | ₩2.23 Billion ≈ $1.51 Million |
+136.53% |
| 2018-12-31 | ₩943.77 Million ≈ $639.58K |
-1.26% |
| 2017-12-31 | ₩955.78 Million ≈ $647.72K |
-7.10% |
| 2016-12-31 | ₩1.03 Billion ≈ $697.21K |
-- |
About Gencurix Inc
Gencurix Inc. provides diagnostic solutions in South Korea. Its products include GenesWell BCT, a multigene diagnostic test for breast cancer; Droplex, a genetic test based on digital PCR platform; eDX, an early diagnosis for cancer with liquid biopsy; GenePro SARS-CoV-2 Test kit; GenoCTC, a circulating tumor cell isolator; and GenePro LAMP Cycler, a portable device for infectious disease detecti… Read more